Inquiry Basket
Loading ......
Filter By Product Search for
APOC3
APOC3 Full Name
apolipoprotein C-III
APOC3 Introduction
APOC3 has emerged as one of the most clinically important lipid metabolism targets in cardiovascular and metabolic disease research, particularly for patients struggling with persistent hypertriglyceridemia despite standard lipid-lowering therapy. APOC3 encodes apolipoprotein C-III (ApoC-III), a small apolipoprotein primarily synthesized in the liver and intestine and carried on triglyceride-rich lipoproteins such as VLDL and chylomicrons, as well as a subset of HDL particles. Over the last decade, large-scale genetic and translational studies have consistently shown that elevated ApoC-III levels are strongly associated with increased plasma triglycerides, accelerated atherosclerosis, and higher risk of cardiovascular events. Clinicians and researchers are particularly interested in APOC3 because naturally occurring loss-of-function variants are linked to lower triglyceride levels and reduced risk of atherosclerotic cardiovascular disease (ASCVD), providing compelling human genetic evidence that APOC3 is not simply a biomarker, but a causal driver of disease progression. This genetic validation has made APOC3 an attractive therapeutic target for next-generation RNA-based medicines and precision lipid therapies.
Functionally, ApoC-III acts as a central regulator of triglyceride metabolism and lipoprotein clearance. One of its most important biological effects is the inhibition of lipoprotein lipase (LPL), the key enzyme responsible for hydrolyzing triglycerides in circulating lipoproteins. By suppressing LPL activity, ApoC-III delays the clearance of triglyceride-rich particles and promotes the accumulation of atherogenic remnant lipoproteins in plasma. In addition, ApoC-III enhances hepatic secretion of VLDL, interferes with receptor-mediated uptake of triglyceride-rich particles by the liver, and increases retention of lipoproteins within the arterial wall, collectively amplifying cardiovascular risk. Emerging evidence also suggests that APOC3 participates in pathways beyond classical lipid metabolism, including endothelial inflammation, endoplasmic reticulum stress, insulin resistance, and vascular smooth muscle proliferation. These mechanisms help explain why elevated APOC3 expression is frequently observed in patients with metabolic syndrome, type 2 diabetes, obesity-associated dyslipidemia, and postprandial hypertriglyceridemia. Researchers are also investigating the role of ApoC-III in neurodegenerative conditions such as Alzheimer's disease, where abnormal lipid transport and chronic inflammation may contribute to disease pathology.
From a disease and therapeutic perspective, APOC3 has become a major focus in the development of targeted treatments for severe hypertriglyceridemia, familial chylomicronemia syndrome (FCS), and residual cardiovascular risk. Patients with markedly elevated triglycerides often remain vulnerable to pancreatitis and cardiovascular complications even after statin therapy, creating an urgent need for more effective triglyceride-lowering strategies. APOC3-targeted therapies, including antisense oligonucleotides and RNA interference agents such as Volanesorsen, Olezarsen, and ARO-APOC3, have demonstrated substantial reductions in circulating ApoC-III and triglyceride levels in clinical studies. While earlier therapies raised concerns regarding thrombocytopenia and tolerability, newer-generation compounds appear to offer improved safety profiles alongside robust lipid-lowering efficacy. Increasing evidence also links APOC3-rich HDL particles with higher cardiovascular risk, challenging the traditional view that all HDL is cardioprotective and highlighting the complexity of lipoprotein biology. As precision medicine continues to evolve, APOC3 is increasingly viewed as a high-value therapeutic and biomarker target with broad implications across cardiovascular disease, diabetes, inflammatory disorders, and lipid metabolism research.
Alternate Names for APOC3
APOC3; apolipoprotein C-III; HALP2; APOCIII; apo-CIII; apoC-III; apolipoprotein C3;
Loading ......
